4-Chloro-2,3-difluorophenol | 1261634-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-Chloro-2,3-difluorophenol
• CAS: 1261634-63-2
• 化学式: C₆H₃ClF₂O
• 分子量: 164.54
• InChiKey: HVLUXBQZVNQLTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS<br/>[FR] TÉTRAHYDROFURANES SUBSTITUÉS EN TANT QUE MODULATEURS DE CANAUX SODIQUES
  申请人：VERTEX PHARMA

  公开号：WO2021113627A1

  公开（公告）日：2021-06-10

  Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.

  提供了作为钠通道抑制剂的化合物及其药用盐。还提供了包含这些化合物或药用盐的药物组合物，以及使用这些化合物、药用盐和药物组合物治疗各种疾病，包括疼痛的方法。
• [EN] CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS<br/>[FR] CHROMÈNE ET 1,1A,2,7B-TÉTRAHYDROCYCLOPROPA[C]CHROMÈNE PYRIDOPYRAZINEDIONES COMME MODULATEURS DE GAMMA-SÉCRÉTASE
  申请人：PFIZER

  公开号：WO2015150957A1

  公开（公告）日：2015-10-08

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. These compounds are γ-secretase modulators, useful for the treatment of neurodegenerative and/ or neurological disorders such as Alzheimer's disease and Down's syndrome.

  所述化合物及其药用可接受盐已被披露，其中所述化合物具有式（I）的结构，其中X、R1、R2a、R2b、R4a、R4b、R5a、R5b、R6、R7、y和z如规范中所定义。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。这些化合物是γ-分泌酶调节剂，可用于治疗神经退行性和/或神经系统疾病，如阿尔茨海默病和唐氏综合征。
• NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES
  申请人：Pfizer Inc.

  公开号：US20150274721A1

  公开（公告）日：2015-10-01

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R 1 , R 2a , R 2b , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明揭示了化合物及其药学上可接受的盐，其中该化合物具有I式结构，其中X、R1、R2a、R2b、R4a、R4b、R5a、R5b、R6、R7、y和z的定义在说明书中。同时还揭示了相应的药物组合物、治疗方法、合成方法和中间体。
• CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS
  申请人：Pfizer Inc.

  公开号：EP3126361A1

  公开（公告）日：2017-02-08
• CHROMENE AND 1,1A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS
  申请人：Pfizer Inc.

  公开号：EP3126361B1

  公开（公告）日：2019-11-06